ライフサイエンスコーパス: ex vivo gene therapy

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 , for release of therapeutic biomolecules in ex vivo gene therapy.

2 udies directed toward liver repopulation and ex vivo gene therapy.

3 ene delivery to a limited cell source, as in ex vivo gene therapy.

4 patient-specific disease modeling, and even ex vivo gene therapy.

5 on, may influence the response of the CNS to ex vivo gene therapy.

6 Potential therapies for DEB include (i) ex vivo gene therapy and (ii) intradermal injection of g

7 To provide cell-binding ligands for ex vivo gene therapy and chronic lymphocytic leukemia (C

8 This study demonstrates that ex vivo gene therapy and subsequent cell transplantation

9 r cells) can serve as efficient vehicles for ex vivo gene therapy and suggest that liver-based geneti

10 rwhelmingly preferred over other methods for ex vivo gene therapy because they provide permanent inte

11 ese procedures to develop a model system for ex vivo gene therapy by repopulating rat livers with hep

12 Liver-directed ex vivo gene therapy can be accomplished safely in human

13 Until recently, progress in ex vivo gene therapy (GT) for human immunodeficiency vir

14 in the type VII collagen gene and for which ex vivo gene therapy has been considered.

15 For decades, autologous ex vivo gene therapy has been postulated as a potential

16 These results provide a model for potential ex vivo gene therapy in the subretinal space.

17 Thus, stem-cell-directed ex vivo gene therapy is capable of restoring phagocyte o

18 the use of genetically modified BM cells for ex vivo gene therapy of GS.

19 In a phase I clinical trial of ex vivo gene therapy of p47phox-deficient CGD, prolonged

20 We have recently shown that ex vivo gene therapy of rabbit autologous vein grafts wi

21 ore provide the basis for safe and efficient ex vivo gene therapy of the hematopoietic system.

22 Cell-cycle blockade by ex-vivo gene therapy of experimental vein grafts inhibit

23 Ex vivo gene therapy strategies avoid systemic delivery

24 uit of definitive therapy for XLA, we tested ex vivo gene therapy using a lentiviral vector (LV) cont

25 tors in bone formation and bone healing with ex vivo gene therapy using muscle-derived stem cells gen

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。